Cadonilimab

Extended indication	In patients with relapsed or metastatic cervical cancer (r/m CC) who have progressed on or after platinum-based chemotherapy
Therapeutic value	No estimate possible yet
Registration phase	Clinical trials

Product

Active substance	Cadonilimab
Domain	Oncology
Reason of inclusion	New medicine (specialité)
Main indication	Cervical cancer
Extended indication	In patients with relapsed or metastatic cervical cancer (r/m CC) who have progressed on or after platinum-based chemotherapy
Manufacturer	Akeso
Mechanism of action	Other, see general comments
Route of administration	Intravenous
Therapeutical formulation	Intravenous drip
Budgetting framework	Intermural (MSZ)
Additional remarks	Werkingsmechanisme: PD-1/CTLA-4 bi-specific antibody.

Registration route	Centralised (EMA)
ATMP	No
Submission date	2024
Expected Registration	2025
Orphan drug	No
Registration phase	Clinical trials
Additional remarks	In de Verenigde Staten bij de FDA aangemerkt als versnelde beoordeling. In China midden 2022 al goedgekeurd.

Current treatment options	Bevacizumab
Therapeutic value	No estimate possible yet
Substantiation	Er loopt een RCT fase 3 studie. Het zal nog enige tijd duren voordat de resultaten bekend zijn.
Frequency of administration	1 times every 3 weeks
References	NCT05063916, NCT04982237, NCT05235516

Patient volume	< 951 Market share is generally not included unless otherwise stated.
References	IKNL 2021 (1);
Additional remarks	In 2021 waren er 951 patiënten bekend met een cervixcarcinoom.

Patient volume

< 951

Market share is generally not included unless otherwise stated.

References

IKNL 2021 (1);

Additional remarks

In 2021 waren er 951 patiënten bekend met een cervixcarcinoom.

There is currently nothing known about the expected cost.

There is currently nothing known about the possible total cost.

There is currently nothing known about off label use.

Indication extension	Yes
Indication extensions	Phase III: Gastric cancer; Liver cancer; Oesophageal cancer
References	AdisInsight

There is currently no futher information available.